These aren't the glory days for med-tech giant Medtronic (NYSE:MDT), as fiscal 2014 will be a pretty weak year from a growth perspective ahead of some significant new product launches in 2015. Even with a high-quality name like Medtronic, that lack of growth can lead to shares languishing as investors are attracted to (or distracted by) more impressive-looking stories in the short term. Although I'm not a passionate bull on Medtronic shares by any stretch, the stock is pretty much what passes for a bargain these days in the larger segment of this industry and I think it's a respectable core holding.
 
Quarterly Results Pretty “Meh” For Medtronic
There wasn't a lot to complain about in Medtronic's fiscal first quarter, but then neither was there much to celebrate. Like many others in this sector, it was a workmanlike quarter for a market still weighed down by adverse pricing, reimbursement, and utilization trends.

SEE: A Checklist For Successful Medical Technology Investment
 
Revenue rose 2% as reported, or about 3% on an organic basis – very slightly below the average of sell-side estimates. Margins were likewise okay-ish. Gross margin was down about 70bp from last year and either 10bp or 50bp below the average (I've seen two different “consensus” figures). Likewise, operating income rose 3% and operating margin expanded slightly (40bp), but that was either just barely above expectation, or a bit below where sell-side numbers were. 
 
If there was one bright spot to the quarter, it was in the international business. Medtronic's international sales rose 15% on a constant currency basis this quarter.
 
Segment Results Mixed As Well
Not unlike the overall results, Medtronic's line-item results were mixed this quarter.
 
Overall cardiac rhythm management (CRM) sales were up about 2%, or just slightly below expectations. While pacemaker sales were stronger than expected (up 6%), analysts stubbornly refuse to accept that St. Jude (NYSE:STJ) and Boston Scientific (NYSE:BSX) are doing alright in ICDs and I think the company's “weak” performance (down 2%, but 3% below expectations) has less to do with the business than those expectations. On a brighter note, atrial fibrilation-related sales were up 22%.
 
Spine was weaker than expected (down 1%), as the company continues to suffer from its problems with the orthobiologic Infuse. Excluding Infuse, Medtronic isn't doing terribly relative to Johnson & Johnson (NYSE:JNJ) or Stryker (NYSE:SYK), but given that biologics are a large part of most spine care businesses, I wouldn't agree that you should exclude it.
 
Cardio was solid, up 6% and 5% ahead of expectations, as CoreValve continues to do well and the stent business is alright. Neuro and diabetes were more mixed – not bad relative to expectations, but not great in absolute terms (up 3% and 1%, respectively), as the new Boston Scientific Precision Spectra gained some traction and the diabetes business suffered from deferrals ahead of the new 530G pump.
 
One bright spot was the Surgical Tech business – up 13% and well ahead (more than 10%) of expectations. With the sluggishness in diabetes, Surg Tech could move Diabetes down to the smallest reported segment momentarily (though I expect the 530G pump to ultimately revive sales).
 
Holding Its Own For Now
All things considered, this is a good enough result for Medtronic. The company is certainly suffering from the launch of new products from rivals and the erosion of the Infuse business, but none of those were (or should have been) unexpected developments. Moreover, I do believe that the company can gain strong initial share with its Simplicity renal denervation product in 2015, as well as the Admiral drug-eluting balloon. I'm a little less certain about the CoreValve launch in the U.S., given Edwards' (NYSE:EW) disappointing U.S. sales, but I still believe it will be a significant product that moves the needle on revenue growth.

SEE: Compound Annual Growth Rate: What You Should Know
 
The Bottom Line
Medtronic has a trailing free cash flow CAGR of 7%, but I'm forecasting less than half that growth rate for the next decade, as the company faces more challenging headwinds from reimbursement, competition, and its own size. Even so, a 3% free cash flow growth rate supports a fair value in range of the high $50s to low $60s, and that appreciation potential isn't too bad for the sector these days. Factor in the company's commitment to establishing itself as a player in emerging markets, and I think you can make a decent enough case for buying Medtronic shares today.
 
Disclosure – At the time of writing, the author did not own shares of any company mentioned in this article.
 
 

Related Articles
  1. Insurance

    A Checklist For Successful Medical Technology Investment

    Find an investment that will give your portfolio a shot in the arm.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Stock Analysis

    5 Reasons Thoratec Corp. Keeps Impressing Investors

    Learn about Thoratec Corporation and its position in its industry. Understand five key factors why the company has impressed investors.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. Earnings Per Share - EPS

    The portion of a company's profit allocated to each outstanding ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!